How to access Onpattro from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi Arabia patient diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Onpattro (patisiran) from their treating neurologist, often working alongside cardiology in a multidisciplinary amyloid clinic at a Riyadh, Jeddah, or Eastern Province tertiary centre. Onpattro is FDA-approved for this indication and developed by Alnylam Pharmaceuticals. Routine stocking through Saudi Arabia hospital pharmacies for this indication is inconsistent, which is why named-patient import through the Saudi Food and Drug Authority (SFDA) is the typical route when a neurologist determines the therapy is clinically indicated.
This guide explains the legal pathway, the documentation your physician prepares, typical timing, how quotes work, and where Reserve Meds fits in.
Ask about Onpattro in Saudi Arabia
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Onpattro is a lipid-nanoparticle-encapsulated siRNA that silences hepatic TTR production. It is administered by intravenous infusion every three weeks, preceded by an on-label premedication regimen, a corticosteroid, an H1 and H2 antihistamine, and acetaminophen, to reduce infusion-related reactions. Eligibility requires genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy, and a cardiac workup to characterise any ATTR-CM overlap. Your neurologist will establish baseline neuropathy impairment scoring (NIS+7), polyneuropathy disability score, quality-of-life measures, and identify an infusion-capable clinic. Compared with subcutaneous siRNA options like Amvuttra, Onpattro requires infusion infrastructure and the premedication routine, a consideration your neurologist weighs with you and your family.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Onpattro legally importable into Saudi Arabia?
Yes, through the SFDA named-patient import framework. The SFDA named-patient route allows a Saudi Arabia-licensed physician to request import of a medicine not locally registered when (a) the medicine has been approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative suits the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. hATTR polyneuropathy has limited disease-specific registered alternatives, which supports clinical rationale.
How the pathway works, step by step
- Consultation with your treating neurologist. TTR genetic report, neuropathy scoring, and a clinical rationale letter documenting the absence of equivalent registered alternatives.
- Baseline assessment. NIS+7, polyneuropathy disability score, cardiac workup (ECG, echocardiogram, NT-proBNP), and identification of an infusion-capable clinic.
- SFDA named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing and premedication plan, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Onpattro from authorised distribution under DSCSA.
- Cold-chain shipment. Onpattro is a refrigerated product; shipment follows validated cold-chain protocols with temperature logging.
- Arrival and infusion. The hospital pharmacy receives the vial; the infusion centre administers the dose with the on-label premedication regimen.
What documentation your physician needs
- Clinical rationale letter confirming hATTR polyneuropathy and Onpattro as the indicated therapy
- Verification of Saudi Arabia medical licence (SCFHS / MOH)
- TTR genetic test result
- Baseline NIS+7 and polyneuropathy disability score
- Cardiac assessment for ATTR-CM overlap
- Planned infusion schedule (every 3 weeks) and premedication regimen
- Infusion-centre identification and accreditation
Reserve Meds provides a physician documentation kit bundling the templates SFDA reviewers expect for rare-disease neurology named-patient imports.
Costs and timing
Medicine price: quote on request. Every case gets a written custom quote before you commit. Reserve Meds provides a transparent, itemised delivered quote, covering product, cold-chain logistics, SFDA documentation handling, customs clearance, and coordination, at the start of intake.
We give you a written timeline estimate for your case before you commit. The every-three-week infusion cadence is then scheduled with the infusion centre.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: Ramadan and Hajj seasons can affect scheduling across Saudi Arabia tertiary centres. Our team coordinates cycle timing with your family's preferences and your infusion centre's calendar.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and SFDA review.
- Logistics. Validated cold-chain shipment to your prescribing hospital pharmacy.
- Dedicated case lead. A named point of contact coordinating the infusion cadence.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions, including infusion administration, remain with your treating neurologist and the infusion centre.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. See our trust and compliance page.
How is Onpattro different from Amvuttra? Both are siRNA therapies for hATTR polyneuropathy. Onpattro is intravenous, dosed every three weeks, and requires pre-infusion steroid/antihistamine/paracetamol premedication. Amvuttra is subcutaneous, dosed every three months, and does not require a premedication routine. Your neurologist selects based on clinical picture, infusion-centre access, and patient preference.
Does my centre need infusion capability? Yes, Onpattro is IV-infused with on-label premedication. Your neurologist will confirm an infusion-capable centre before intake.
Will private insurance cover this? Cash-pay is the default. Some Saudi Arabia private insurers reimburse named-patient imports on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Onpattro in Saudi Arabia if it is not approved or available there?
Reserve Meds coordinates US-sourced Onpattro for patients in Saudi Arabia through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Saudi Arabia and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Onpattro in Saudi Arabia through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Onpattro. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Saudi Arabia, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Onpattro in Saudi Arabia through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Onpattro to a patient in Saudi Arabia?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Onpattro to your treating physician or hospital pharmacy in Saudi Arabia, with appropriate handling for the product.
How long does it take, and what does Onpattro in Saudi Arabia cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Onpattro in Saudi Arabia?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.